HIMS Blowout Q3 Leads To Substantial Fair Value Bump

Hims & Hers delivered yet another blowout result for Q3 - this one the most impressive yet. Revenue growth accelerated to 77%, on the back of both the GLP-1 weight loss drug launch, and the 44% subscriber growth it helped drive. Even ex-GLP sales, revenues soared 40%. The weight loss drug launch has also supercharged the Hers brand, giving the company yet another growth avenue. The stock is up over 150% since we added it a year ago, but now looks like as good a time as ever to add. The fair value gets a substantial bump from $21 to $28.

Watch List

WDAY -13.18%
VEEV 12.52%
PSTG -7.13%
INTU 14.19%
CMG 31.78%
RDDT 7.17%
NTNX 17.22%
CRWD 76.14%
SE 19.26%
SNOW 5.28%
APPF 6.95%

Buy List

PINS -37.54%
ASML -25.06%
SEMR -37.55%
TSM -43.44%
ZETA -32.89%
GOOG -51.47%
NYAX -30.39%
MSFT -31.81%
ODD -32.30%
ASR -26.98%
FLYW -44.52%
HRMY -60.41%
YOU -37.20%
ABNB -33.55%
MELI -26.26%
ADBE -45.26%

Hold List

VTEX -17.92%
CELH 49.08%
TOST 16.30%
CPNG -14.83%
HIMS -23.69%
PAYC -21.14%
MNDY 7.35%
GLBE -24.43%
ZS 23.06%
V -7.38%
ADSK -2.06%
NOW -1.85%
FTNT -4.90%
TEAM -8.65%